NO314801B1 - Nye cyanoindol serotonin-reopptaks-inhibitorforbindelser og farmasöytiske sammensetninger inneholdende dem - Google Patents

Nye cyanoindol serotonin-reopptaks-inhibitorforbindelser og farmasöytiske sammensetninger inneholdende dem Download PDF

Info

Publication number: NO314801B1
Authority: NO; Norway
Prior art keywords: group; alkyl; indole; pharmaceutically acceptable; formula
Prior art date: 1999-01-26

Application number

NO20000373A

Other languages

English (en)

Norwegian (no)

Other versions

NO20000373D0 (no

NO20000373L (no

Inventor

Gilbert Lavielle

Olivier Muller

Bernard Cimetiere

Mark Millan

Alain Gobert

Jean-Michel Rivet

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-26

Filing date

2000-01-25

Publication date

2003-05-26

2000-01-25 Application filed by Servier Lab filed Critical Servier Lab

2000-01-25 Publication of NO20000373D0 publication Critical patent/NO20000373D0/no

2000-07-27 Publication of NO20000373L publication Critical patent/NO20000373L/no

2003-05-26 Publication of NO314801B1 publication Critical patent/NO314801B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 54
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
239000003772 serotonin uptake inhibitor Substances 0.000 title claims description 4
229940126570 serotonin reuptake inhibitor Drugs 0.000 title claims description 3
CBTITARLOCZPDU-UHFFFAOYSA-N 1h-indole-2-carbonitrile Chemical compound C1=CC=C2NC(C#N)=CC2=C1 CBTITARLOCZPDU-UHFFFAOYSA-N 0.000 title abstract 3
125000000217 alkyl group Chemical group 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 10
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
239000002253 acid Substances 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
125000001041 indolyl group Chemical group 0.000 claims description 8
125000004093 cyano group Chemical group *C#N 0.000 claims description 7
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
208000019901 Anxiety disease Diseases 0.000 claims description 2
206010013654 Drug abuse Diseases 0.000 claims description 2
206010029333 Neurosis Diseases 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
230000036506 anxiety Effects 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 claims description 2
208000015238 neurotic disease Diseases 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
208000019899 phobic disease Diseases 0.000 claims description 2
125000004193 piperazinyl group Chemical group 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
208000011117 substance-related disease Diseases 0.000 claims description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 5
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
125000003118 aryl group Chemical group 0.000 abstract description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract description 2
125000000592 heterocycloalkyl group Chemical group 0.000 abstract description 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 5
125000004450 alkenylene group Chemical group 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000004419 alkynylene group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000003107 substituted aryl group Chemical group 0.000 abstract 1
238000004452 microanalysis Methods 0.000 description 28
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
238000000034 method Methods 0.000 description 26
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 19
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 10
239000012074 organic phase Substances 0.000 description 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
238000010494 dissociation reaction Methods 0.000 description 6
230000005593 dissociations Effects 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
230000000697 serotonin reuptake Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
-1 3-(Dimethylamino)propyn-1H-indole-6-carbonitrile hydrochloride Chemical compound 0.000 description 5
238000011534 incubation Methods 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
239000003480 eluent Substances 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000004448 titration Methods 0.000 description 4
PURSZYWBIQIANP-UHFFFAOYSA-N 1-(bromomethyl)-2-chlorobenzene Chemical compound ClC1=CC=CC=C1CBr PURSZYWBIQIANP-UHFFFAOYSA-N 0.000 description 3
SZSZDBFJCQKTRG-UHFFFAOYSA-N 1h-indole-6-carbonitrile Chemical compound N#CC1=CC=C2C=CNC2=C1 SZSZDBFJCQKTRG-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000027455 binding Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000001816 cooling Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
238000010992 reflux Methods 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 2
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 2
IDMFVGRBITWGLW-UHFFFAOYSA-N 5-methoxy-4-piperazin-1-ylpyrimidine Chemical compound COC1=CN=CN=C1N1CCNCC1 IDMFVGRBITWGLW-UHFFFAOYSA-N 0.000 description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
101150013372 Htr2c gene Proteins 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
206010033664 Panic attack Diseases 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
238000005567 liquid scintillation counting Methods 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
208000019906 panic disease Diseases 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
BPORFBCKDWURMY-UHFFFAOYSA-N 1-(3-hydroxypropyl)indole-6-carbonitrile Chemical compound C1=C(C#N)C=C2N(CCCO)C=CC2=C1 BPORFBCKDWURMY-UHFFFAOYSA-N 0.000 description 1
IOMUZEKWKYQAOW-UHFFFAOYSA-N 1-(5-methoxypyrimidin-4-yl)-1,4-diazepane Chemical compound COC1=CN=CN=C1N1CCNCCC1 IOMUZEKWKYQAOW-UHFFFAOYSA-N 0.000 description 1
LZIYAIRGDHSVED-UHFFFAOYSA-N 1-(bromomethyl)-3-chlorobenzene Chemical compound ClC1=CC=CC(CBr)=C1 LZIYAIRGDHSVED-UHFFFAOYSA-N 0.000 description 1
GECZNSYGSXFGRV-UHFFFAOYSA-N 1-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]indole-6-carbonitrile Chemical compound COC1=CN=CN=C1N1CCN(CCCN2C3=CC(=CC=C3C=C2)C#N)CC1 GECZNSYGSXFGRV-UHFFFAOYSA-N 0.000 description 1
LHVBYQSGIAMUJC-UHFFFAOYSA-N 1-[[1-[(2-chlorophenyl)methyl]pyrrolidin-3-yl]methyl]indole-5-carbonitrile;hydrochloride Chemical compound Cl.ClC1=CC=CC=C1CN1CC(CN2C3=CC=C(C=C3C=C2)C#N)CC1 LHVBYQSGIAMUJC-UHFFFAOYSA-N 0.000 description 1
USYQKCQEVBFJRP-UHFFFAOYSA-N 1-bromo-3-phenylbenzene Chemical compound BrC1=CC=CC(C=2C=CC=CC=2)=C1 USYQKCQEVBFJRP-UHFFFAOYSA-N 0.000 description 1
NHWOUHPVTRAOTN-UHFFFAOYSA-N 1-chloro-5-(2-chloroethyl)-3H-indol-2-one Chemical compound ClN1C(CC2=CC(=CC=C12)CCCl)=O NHWOUHPVTRAOTN-UHFFFAOYSA-N 0.000 description 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
YHYLDEVWYOFIJK-UHFFFAOYSA-N 1h-indole-5-carbonitrile Chemical compound N#CC1=CC=C2NC=CC2=C1 YHYLDEVWYOFIJK-UHFFFAOYSA-N 0.000 description 1
125000003163 2-(2-naphthyl)ethyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(C([H])=C([H])C2=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 1
SVZSNASRUSJMAF-UHFFFAOYSA-N 6-(2-chloroethyl)-7-methyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound O=C1C(CCCl)=C(C)N=C2SC=CN21 SVZSNASRUSJMAF-UHFFFAOYSA-N 0.000 description 1
KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical group C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000004659 Presynaptic Receptors Human genes 0.000 description 1
108010003717 Presynaptic Receptors Proteins 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical group C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Substances ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
229960001653 citalopram Drugs 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000005153 frontal cortex Anatomy 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
150000002475 indoles Chemical group 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229960003955 mianserin Drugs 0.000 description 1
239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
230000007170 pathology Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
235000012976 tarts Nutrition 0.000 description 1
KJXABDBFZJRAFZ-UHFFFAOYSA-N tert-butyl 3-[(2-methylphenyl)sulfonyloxymethyl]pyrrolidine-1-carboxylate Chemical compound CC1=CC=CC=C1S(=O)(=O)OCC1CN(C(=O)OC(C)(C)C)CC1 KJXABDBFZJRAFZ-UHFFFAOYSA-N 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Veterinary Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

NO20000373A 1999-01-26 2000-01-25 Nye cyanoindol serotonin-reopptaks-inhibitorforbindelser og farmasöytiske sammensetninger inneholdende dem NO314801B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9900801A FR2788772B1 (fr)	1999-01-26	1999-01-26	Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number	Publication Date
NO20000373D0 NO20000373D0 (no)	2000-01-25
NO20000373L NO20000373L (no)	2000-07-27
NO314801B1 true NO314801B1 (no)	2003-05-26

Family

ID=9541208

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20000373A NO314801B1 (no)	1999-01-26	2000-01-25	Nye cyanoindol serotonin-reopptaks-inhibitorforbindelser og farmasöytiske sammensetninger inneholdende dem

Country Status (22)

Country	Link
US (1)	US6239129B1 (zh)
EP (1)	EP1023898B1 (zh)
JP (1)	JP2000212162A (zh)
KR (1)	KR100445389B1 (zh)
CN (1)	CN1155570C (zh)
AT (1)	ATE234093T1 (zh)
AU (1)	AU761084B2 (zh)
BR (1)	BR0000158A (zh)
CA (1)	CA2297279C (zh)
DE (1)	DE60001591T2 (zh)
DK (1)	DK1023898T3 (zh)
EA (1)	EA003146B1 (zh)
ES (1)	ES2193923T3 (zh)
FR (1)	FR2788772B1 (zh)
HK (1)	HK1029584A1 (zh)
HU (1)	HUP0000308A2 (zh)
MX (1)	MXPA00000856A (zh)
NO (1)	NO314801B1 (zh)
NZ (1)	NZ502494A (zh)
PL (1)	PL338027A1 (zh)
SI (1)	SI1023898T1 (zh)
ZA (1)	ZA200000336B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001247562A (ja) *	2000-03-07	2001-09-11	Daicel Chem Ind Ltd	アミド化合物及びその製造方法
AU2426602A (en) *	2000-11-20	2002-05-27	Biovitrum Ab	Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
SE0004245D0 (sv)	2000-11-20	2000-11-20	Pharmacia Ab	Novel compounds and their use
WO2002079152A1 (en)	2001-03-29	2002-10-10	Bristol-Myers Squibb Company	Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
NZ537982A (en) *	2002-09-17	2007-05-31	Hoffmann La Roche	2,7-substituted indoles and their use as 5-HT6 modulators
US7129264B2 (en) *	2003-04-16	2006-10-31	Bristol-Myers Squibb Company	Biarylmethyl indolines and indoles as antithromboembolic agents
EP1689389A4 (en) *	2003-12-04	2009-06-17	Nat Health Research Institutes	Indole compounds
FR2884251B1 (fr) *	2005-04-08	2007-07-13	Servier Lab	Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015066344A1 (en)	2013-11-01	2015-05-07	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists and compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK181190D0 (da) *	1990-07-30	1990-07-30	Lundbeck & Co As H	3-aryl-indol- eller 3-aryl-indazolderivater
TW270114B (zh) *	1993-10-22	1996-02-11	Hoffmann La Roche
DE19500689A1 (de) *	1995-01-12	1996-07-18	Merck Patent Gmbh	Indolpiperidin-Derivate
US5912256A (en) *	1996-06-20	1999-06-15	Eli Lilly And Company	Compounds having effects on serotonin-related systems
JP3560986B2 (ja) *	1997-01-13	2004-09-02	山之内製薬株式会社	５―ｈｔ２ｃ受容体作用薬及びアミノアルキルインダゾール誘導体

1999
- 1999-01-26 FR FR9900801A patent/FR2788772B1/fr not_active Expired - Fee Related
2000
- 2000-01-24 CA CA002297279A patent/CA2297279C/fr not_active Expired - Fee Related
- 2000-01-24 JP JP14544A patent/JP2000212162A/ja active Pending
- 2000-01-25 EA EA200000068A patent/EA003146B1/ru not_active IP Right Cessation
- 2000-01-25 NZ NZ502494A patent/NZ502494A/en unknown
- 2000-01-25 NO NO20000373A patent/NO314801B1/no unknown
- 2000-01-25 AU AU13553/00A patent/AU761084B2/en not_active Ceased
- 2000-01-25 PL PL00338027A patent/PL338027A1/xx not_active Application Discontinuation
- 2000-01-25 KR KR10-2000-0003388A patent/KR100445389B1/ko not_active IP Right Cessation
- 2000-01-25 MX MXPA00000856A patent/MXPA00000856A/es not_active IP Right Cessation
- 2000-01-25 BR BR0000158-9A patent/BR0000158A/pt not_active Withdrawn
- 2000-01-25 US US09/490,909 patent/US6239129B1/en not_active Expired - Fee Related
- 2000-01-26 DK DK00400193T patent/DK1023898T3/da active
- 2000-01-26 ZA ZA200000336A patent/ZA200000336B/xx unknown
- 2000-01-26 DE DE60001591T patent/DE60001591T2/de not_active Expired - Fee Related
- 2000-01-26 AT AT00400193T patent/ATE234093T1/de not_active IP Right Cessation
- 2000-01-26 ES ES00400193T patent/ES2193923T3/es not_active Expired - Lifetime
- 2000-01-26 CN CNB001011561A patent/CN1155570C/zh not_active Expired - Fee Related
- 2000-01-26 SI SI200030063T patent/SI1023898T1/xx unknown
- 2000-01-26 EP EP00400193A patent/EP1023898B1/fr not_active Expired - Lifetime
- 2000-01-26 HU HU0000308A patent/HUP0000308A2/hu unknown
2001
- 2001-01-12 HK HK01100310A patent/HK1029584A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2193923T3 (es)	2003-11-16
CN1155570C (zh)	2004-06-30
FR2788772A1 (fr)	2000-07-28
US6239129B1 (en)	2001-05-29
DE60001591D1 (de)	2003-04-17
EA003146B1 (ru)	2003-02-27
SI1023898T1 (en)	2003-06-30
CA2297279C (fr)	2004-05-18
DE60001591T2 (de)	2003-12-24
EA200000068A3 (ru)	2000-10-30
HUP0000308A2 (en)	2002-06-29
DK1023898T3 (da)	2003-06-10
FR2788772B1 (fr)	2001-03-02
NO20000373D0 (no)	2000-01-25
MXPA00000856A (es)	2002-03-08
JP2000212162A (ja)	2000-08-02
EP1023898A1 (fr)	2000-08-02
BR0000158A (pt)	2000-09-19
EA200000068A2 (ru)	2000-08-28
ZA200000336B (en)	2000-08-15
AU1355300A (en)	2000-07-27
AU761084B2 (en)	2003-05-29
HU0000308D0 (en)	2000-03-28
ATE234093T1 (de)	2003-03-15
HK1029584A1 (en)	2001-04-06
EP1023898B1 (fr)	2003-03-12
KR100445389B1 (ko)	2004-08-25
NO20000373L (no)	2000-07-27
PL338027A1 (en)	2000-07-31
NZ502494A (en)	2001-06-29
CN1266057A (zh)	2000-09-13
CA2297279A1 (fr)	2000-07-26
KR20010006587A (ko)	2001-01-26

Publication	Publication Date	Title
US5834493A (en)	1998-11-10	Indole derivatives as 5-HT1A and/or 5-HT2 ligands
TWI242004B (en)	2005-10-21	1-(1-substituted-4-piperidinyl)methyl-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
EP0690843B1 (en)	2000-08-30	Formyl- or cyano- substituted indole derivatives having dopaminergic activity
EP1727794B1 (en)	2011-11-16	Novel benzyl(idene)-lactam derivatives
TW200526640A (en)	2005-08-16	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
NO334383B1 (no)	2014-02-24	Fremgangsmåte for fremstilling av av CF3-substituerte pyrimidiner
NZ517661A (en)	2004-02-27	Aminoalkoxy carbazoles and their use as 5-HT ligands for the treatment of CNS diseases
NO314801B1 (no)	2003-05-26	Nye cyanoindol serotonin-reopptaks-inhibitorforbindelser og farmasöytiske sammensetninger inneholdende dem
NZ500386A (en)	2002-05-31	Ergoline derivatives and their use as somatostatin receptor antagonists
JP2006519812A (ja)	2006-08-31	フェニルスルホン誘導体およびｃｎｓ障害の治療におけるその使用
JPH04234860A (ja)	1992-08-24	チアジン（又はオキサジン）誘導体、その製法及びその合成中間体
JP2011515359A (ja)	2011-05-19	治療用トリアゾールアミド誘導体
DK156722B (da)	1989-09-25	Analogifremgangsmaade til fremstilling af 2-piperazinopyrimidinderivater
US6242448B1 (en)	2001-06-05	Trisubstituted-oxazole derivatives as serotonin ligands
NO322966B1 (no)	2006-12-18	Nye oktahydro-2H-pyrido[1-2-a]pyrazinforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem
US5071845A (en)	1991-12-10	Benzoxazepine derivative
NZ541944A (en)	2008-05-30	4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
SK172799A3 (en)	2000-06-12	3-benzylpiperidine derivative, process for its preparation and pharmaceutical composition containing the same
SK2192002A3 (en)	2002-06-04	Piperidine alcohol derivative, process for the preparation and use thereof and pharmaceutical composition comprising same
EP2361246A1 (en)	2011-08-31	Oxopiperidinyl and pyranyl sulfonamides as ampa potentiators
NO321242B1 (no)	2006-04-10	Nye cyanoindol serotonin-reopptaks-inhibitorforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem
EP2324035A1 (en)	2011-05-25	Substituted n-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands
WO2004113344A1 (ja)	2004-12-29	ピラゾロピリミジン化合物のメタンスルホン酸塩、その結晶およびその製造方法
EP0130202A1 (en)	1985-01-09	Tetracyclic compounds
WO1984002704A1 (en)	1984-07-19	Tetracyclic compounds